GlassScriptPhysician profile
Aarti Shevade
NPI 1548420888
$13,889.00
in general payments reported to CMS, 2019-2025
84 companies · $3,030 in 2025
The $3,030 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,856 · 2020: $600 · 2021: $269 · 2022: $1,971 · 2023: $2,972 · 2024: $3,191 · 2025: $3,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,994 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,993.67 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,128.00 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Novartis Pharmaceuticals Corporation | $908.61 | 2020-2025 | |
| Eisai INC. | $841.59 | 2019-2025 | |
| Genentech USA, INC. | $808.52 | 2019-2025 | Venclexta, Polivy, Itovebi |
| Celgene Corporation | $713.46 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Merck Sharp & Dohme LLC | $661.26 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $591.32 | 2019-2025 | Verzenio, Jaypirca |
| Astellas Pharma US INC | $521.77 | 2019-2025 | Xtandi, Xospata, Padcev |
| Genzyme Corporation | $469.86 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $439.10 | 2019-2024 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $350.28 | 2019-2025 | Carvykti, Tecvayli, Darzalex |
| Glaxosmithkline, LLC. | $347.02 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $336.67 | 2022-2025 | |
| Incyte Corporation | $324.01 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $297.58 | 2022-2025 | Libtayo |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $290.46 | 2019-2023 | Adcetris |
| Gilead Sciences, INC. | $280.42 | 2021-2025 | Trodelvy |
| Pfizer INC. | $251.22 | 2019-2025 | |
| Daiichi Sankyo INC. | $236.44 | 2020-2025 | Enhertu, Vanflyta |
| Amgen INC. | $236.26 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Takeda Pharmaceuticals U.S.A., INC. | $228.41 | 2019-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Pharmacyclics LLC, An Abbvie Company | $220.75 | 2019-2023 | Imbruvica |
| Sobi, INC | $196.83 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $174.89 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.06 | 2021-2025 | |
| Boston Scientific Corporation | $164.43 | 2025 | Therasphere Administration Set |
| Kite Pharma, INC. | $157.62 | 2019-2025 | Yescarta |
| Blueprint Medicines Corporation | $146.38 | 2022-2023 | Ayvakit |
| Karyopharm Therapeutics INC. | $132.09 | 2021-2025 | Xpovio |
| Ipsen Biopharmaceuticals, INC | $118.71 | 2019-2025 | Somatuline Depot, Onivyde |
| Puma Biotechnology, INC. | $117.23 | 2024-2025 | |
| Genmab U.S., INC. | $95.12 | 2023-2025 | Tivdak, Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.14 | 2021-2025 | Gilotrif |
| Foundation Medicine, INC. | $77.08 | 2019-2023 | Foundationone Cdx |
| Springworks Therapeutics, INC. | $76.42 | 2024-2025 | Ogsiveo, Gomekli |
| Mirati Therapeutics, INC. | $73.13 | 2023-2024 | Krazati |
| Beigene USA, INC. | $72.70 | 2023-2024 | Brukinsa |
| Emd Serono, INC. | $71.64 | 2023-2024 | |
| Beone Medicines USA, INC. | $69.97 | 2025 | Brukinsa, Tevimbra |
| Stemline Therapeutics INC. | $67.75 | 2019-2024 | Orserdu |
| Exelixis INC. | $65.60 | 2022-2025 | Cabometyx |
| Novocure INC. | $63.96 | 2024 | Optune, Optune Lua (Novottf-200t) |
| Tempus Ai, INC | $62.38 | 2024-2025 | Xt Cdx |
| Acrotech Biopharma INC. | $57.01 | 2022-2024 | Beleodaq |
| Epizyme, INC. | $55.02 | 2022 | |
| Pharmaessentia USA Corporation | $48.74 | 2023-2025 | Besremi |
| Dova Pharmaceuticals | $46.76 | 2019-2020 | |
| Aveo Pharmaceuticals, INC. | $43.60 | 2022-2025 | |
| Spectrum Pharmaceuticals INC. | $41.16 | 2023-2025 | Rolvedon |
| Rigel Pharmaceuticals, INC. | $40.34 | 2023-2024 | Rezlidhia, Tavalisse |
| Morphosys, US INC. | $39.93 | 2023 | Monjuvi |
| Immunocore Limited | $37.51 | 2024 | Kimmtrak |
| Tesaro, INC. | $35.88 | 2019 | |
| Agios Pharmaceuticals, INC. | $35.68 | 2022-2023 | Pyrukynd |
| Sumitomo Pharma America, INC. | $33.85 | 2023-2025 | Orgovyx |
| Adaptive Biotechnologies Corporation | $33.03 | 2022-2023 | Clonoseq |
| Organon LLC | $32.00 | 2023 | Ontruzant |
| Immunogen, INC. | $29.96 | 2024 | Elahere |
| Heron Therapeutics, INC. | $26.99 | 2022 | |
| Tersera Therapeutics LLC | $26.53 | 2024 | Quzyttir |
| Legend Biotech USA INC. | $26.19 | 2025 | Carvykti |
| Alexion Pharmaceuticals, INC. | $24.72 | 2023 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $24.34 | 2024 | Qinlock |
| Servier Pharmaceuticals LLC | $24.00 | 2024 | |
| G1 Therapeutics, INC. | $23.56 | 2023 | Cosela |
| Fennec Pharmaceuticals, INC. | $23.04 | 2024 | Pedmark |
| Global Blood Therapeutics, INC. | $23.02 | 2022 | |
| Caris Mpi, INC. | $22.98 | 2025 | Mi Cancer Seek |
| Mylan Institutional INC. | $21.88 | 2023 | Fulphila, Ogivri |
| Pharmacosmos Therapeutics INC. | $20.36 | 2023 | Monoferric |
| Verastem, INC. | $20.27 | 2019 | |
| Adc Therapeutics America, INC. | $20.08 | 2024 | |
| Recordati_rare_diseases_inc. | $19.72 | 2025 | Sylvant |
| Progenics Pharmaceuticals, INC. | $19.67 | 2025 | |
| Kyowa Kirin, INC. | $19.58 | 2023 | Poteligeo |
| Myovant Sciences INC. | $19.49 | 2022 | |
| Amneal Pharmaceuticals LLC | $18.38 | 2023 | Avastin |
| Eusa Pharma (US) LLC | $16.67 | 2021 | |
| Array Biopharma INC | $16.55 | 2025 | Mektovi, Braftovi |
| Cumberland Pharmaceuticals, INC. | $15.06 | 2023 | Sancuso |
| Teva Pharmaceuticals USA, INC. | $14.77 | 2019 | |
| Secura Bio, INC. | $14.53 | 2024 | Copiktra |
| Coherus Oncology, INC. | $13.65 | 2024 | |
| Taiho Oncology, INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
Lenvima $593Venclexta $489Enhertu $467Verzenio $317Libtayo $268Imbruvica $225Trodelvy $217Keytruda $212Lynparza $208Reblozyl $191Kisqali $185Carvykti $176Zepzelca $175Therasphere Administration Set $164Doptelet $157Imfinzi $155Pluvicto $150Brukinsa $129Opdivo $129Sarclisa $124Ojjaara $122Monjuvi $102Lutathera $102Scemblix $97.98Yescarta $96.19Ninlaro $93.28Cablivi $91.23Elahere $86.68Xtandi $84.65Stivarga $83.97Vitrakvi $83.97Calquence $83.35Ayvakit $83.05Xpovio $80.96Adcetris $79.64Nubeqa $77.72Opdualag $76.16Vanflyta $75.02Epkinly $73.71Krazati $73.13Tagrisso $72.74Alunbrig $70.62Jaypirca $68.01Fabhalta $65.09Enjaymo $63.95Xospata $63.63Padcev $58.02Tecvayli $57.92Somatuline Depot $55.29Onivyde $55.29Xofigo $55.21Nerlynx $54.68Cabometyx $51.35Darzalex $49.85Welireg $49.17Elrexfio $49.03Jakafi $48.81Besremi $48.74Jevtana $48.35Tivdak $47.60Zejula $45.60Jemperli $45.60Ogsiveo $43.15Orserdu $41.27Optune $41.21Rolvedon $41.16Tavalisse $40.34Rezlidhia $40.34Xt Cdx $39.43Pemazyre $38.86Beleodaq $38.65Polivy $38.12Kimmtrak $37.51Piqray $37.46Tukysa $35.65Mekinist $35.21Tasigna $35.16Lumakras $34.57Orgovyx $33.85Gomekli $33.27Ontruzant $32.00Talvey $31.27Vyloy $31.18Fruzaqla $27.89Quzyttir $26.53Fotivda $25.32Rybrevant $24.90Ultomiris $24.72Pomalyst $24.65Bosulif $24.56Qinlock $24.34Idhifa $24.00Itovebi $23.83Keytruda Qlex $23.71Zynyz $23.70Cosela $23.56Pedmark $23.04Mi Cancer Seek $22.98Optune Lua (Novottf-200t) $22.75Ogivri $21.88
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aarti Shevade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.